Expired activity
Please go to the PowerPak homepage and select a course.

Employing Immuno-Oncology Biomarkers to Guide Treatment Decision- Making: Managed Care and Specialty Pharmacist Perspectives

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.


Lisa Davis, PharmD, FCCP, BCPS, BCOP
Professor, Pharmacy Practice and Science
University of Arizona College of Pharmacy
Oncology Clinical Pharmacist
Banner University Medical Center
Tucson, AZ

Matthew Farber, MA
Senior Director, Patient Care and Advocacy:
Oncology, Fertility & Multiple Sclerosis
Walgreens Company


Dr. Davis has no relevant affiliations or financial relationships with a commercial interest to disclose.

Mr. Farber has disclosed that he owns stock in the Walgreens Boots Alliance.

The clinical reviewer, Megan May, PharmD, BCOP, has no actual or potential conflict of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-19-019-L01-P
Credits: 1.5 hour (0.15 ceu)

Type of Activity: Application 
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 90 minutes

Date of Activity

CE symposium at ASEMBIA 2019
Las Vegas, NV

Monday, April 29, 2019
4:30 – 6:00 PM PT


This accredited activity has been designed for managed care and specialty pharmacists.


Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live symposium; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.


The goal of this educational activity is to provide pharmacists practicing in managed care and specialty pharmacy settings with education focused on contemporary uses of biomarkers in immuno-oncology treatment decision making and how pharmacists can play a role in many aspects of both drug therapy and formulary management thus leading to improved access to care and outcomes.


Upon completion of this program, participants should be better able to:

  • Describe the potential biomarkers being examined to predict response to immunotherapy
  • Compare the treatment options for biomarker based immunotherapy management for formulary inclusion
  • Analyze the costs and benefits of utilizing biomarkers in determining immunotherapy treatment
  • Describe the data that should be considered when completing the formulary review process for biomarker and immunotherapy options

Presentation Handout(s)

Click below here to Download:


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, ASEMBIA, Bristol-Myers Squibb or Merck & Co., Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

Take Evaluation